EMRIS Pharma
Developing a topical, site-restricted drug-delivery approach to prevent skin toxicities caused by targeted oncology therapies. The company focuses on preclinical research, topical formulation and localized blockade of drug-receptor interactions in skin, and has filed international patent protection and published preclinical results.
Industries
health-care
medical
pharmaceutical
wellness
Nr. of Employees
small (1-50)
Products
Topical formulation for prevention of oncology drug–induced skin toxicities
A first-in-class topical product concept designed to block systemic oncology drugs at the skin toxicity site, preventing local adverse effects while preserving systemic anti-cancer activity.
Topical formulation for prevention of oncology drug–induced skin toxicities
A first-in-class topical product concept designed to block systemic oncology drugs at the skin toxicity site, preventing local adverse effects while preserving systemic anti-cancer activity.
Services
Industry engagement and partnership development
Attendance and presentations at conferences and industry events to pursue collaborations and commercialization opportunities.
Industry engagement and partnership development
Attendance and presentations at conferences and industry events to pursue collaborations and commercialization opportunities.
Expertise Areas
- Topical drug delivery
- Preclinical drug development
- Dermatologic safety for oncology therapies
- Intellectual property and patenting
Key Technologies
- Topical/dermal formulation
- Localized receptor-blocking approach
- Preclinical in vivo efficacy models
- Mechanism-based prevention of drug toxicities